Your session is about to expire
← Back to Search
Heparin Priming for Pancreatic Mass Biopsy
Study Summary
This trial will enroll patients who are scheduled for an endoscopic biopsy of a pancreas lesion. The patients will be randomly assigned to either the heparin or saline group. The hypothesis for this study is that fine needle biopsy tissue quality of pancreatic masses decreases with increasing pass number due to blood contamination; this blood contamination can be ameliorated with priming of the needle with an anticoagulant such as heparin.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Heparin priming biopsies
- Group 2: Standard of care (saline)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
What is the current enrollment of participants in this research endeavor?
"Affirmative. According to clinicaltrials.gov, this research is actively recruiting participants. Initially posted on March 12th 2021, the trial seeks 100 individuals from a single site for participation."
Are there any slots still available for enrollees in this experiment?
"Affirmative. According to the information accessible on clinicaltrials.gov, this medical trial is recruiting patients with an enrollment goal of 100 individuals across 1 site. It was initially posted in March 2021 and recently updated in April 2022."
Have prior investigations explored the usage of Heparin in BD PosiFlush™ Pre-Filled Heparin Lock Flush Syringe priming?
"Currently, 36 clinical trials are underway on the efficacy of Heparin in needle priming. Of these studies, 12 have progressed to Stage 3. While most sites conducting this research can be found in Sherbrooke, Quebec; there is a total of 367 locations running examinations for this medical intervention."
What therapeutic purpose is served by the frequent use of Heparin (BD PosiFlush™ Pre-Filled Heparin Lock Flush Syringe)?
"In addition to its use in medical device priming, heparin (BD PosiFlush™ Pre-Filled Heparin Lock Flush Syringe) can be employed therapeutically for sprains, unstable angina pectoris and atrial fibrillation."
Does this research represent an unprecedented approach?
"Currently, there are 36 active clinical trials associated with Ash Access Technology's Heparin product (BD PosiFlush™ Pre-Filled Heparin Lock Flush Syringe) in 197 cities from 21 different nations. This drug first underwent a Phase 3 trial back in 2006 and has since gone through 620 more separate studies, involving 415 participants."
Share this study with friends
Copy Link
Messenger